Stay updated with breaking news from Px3330. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy after 24 Weeks of Treatment Oral. | January 25, 2023 ....
New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia First update on recruitment in APX3330 ZETA-1 Phase 2b trial: ~70% patients. | January 31, 2022 ....